Pfizer Inc. (NYSE:PFE) Stock Position Cut by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 2.9% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 658,061 shares of the biopharmaceutical company’s stock after selling 19,866 shares during the period. Mutual of America Capital Management LLC’s holdings in Pfizer were worth $16,675,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Clarity Asset Management Inc. bought a new position in Pfizer in the 4th quarter valued at about $27,000. Gould Capital LLC grew its position in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares in the last quarter. North Capital Inc. bought a new position in Pfizer in the 1st quarter valued at about $28,000. Bernard Wealth Management Corp. bought a new position in Pfizer in the 4th quarter valued at about $30,000. Finally, Curio Wealth LLC bought a new position in shares of Pfizer during the 4th quarter valued at about $32,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of several research reports. HSBC reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Monday, May 19th. Citigroup raised their price objective on shares of Pfizer from $23.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Berenberg Bank reduced their price objective on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. BMO Capital Markets reduced their price objective on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Finally, Jefferies Financial Group raised their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.55.

Pfizer Stock Performance

PFE stock opened at $25.65 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The stock has a market cap of $145.83 billion, a P/E ratio of 18.59, a P/E/G ratio of 0.94 and a beta of 0.58. The firm has a 50 day simple moving average of $23.89 and a 200 day simple moving average of $24.79. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same period last year, the company posted $0.82 earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.71%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.